Given that the PI3K/AKT pathway plays a significant role in oncogenesis,47 and that a common side effect associated with the administration of PI3K pathway inhibitors is fatigue,48 our findings suggest that this dysregulation of this pathway, either by cancer or its treatment, may be integral to the development and/or maintenance of CRF. Here, AKT1 is linked to cancer.